Konkuk University Team Reports Urine-Derived Stem Cell Platform Restores Erectile Function Indicator in Nerve-Injured Rats
For the rat study, researchers reprogrammed urine-derived stem cells into induced pluripotent stem cells, introduced the NGF gene, and differentiated them into neural crest cells.

Key Points
- Researchers at Konkuk University and collaborating institutions have developed a preclinical platform combining urine-derived stem cells, nerve growth factor (NGF), and a 3D-printed biodegradable scaffold for erectile dysfunction after prostate cancer surgery.
- In rats with injured cavernous nerves, the combination of NGF-expressing neural crest cells and the scaffold restored erectile function indicators to levels similar to normal rats and reduced tissue cell death and fibrosis, while either component alone produced only partial improvement.
- The findings were published online in Bioactive Materials, and the researchers plan to evaluate the platform in non-nerve-sparing surgery models and assess long-term durability.
Stem cell regeneration engineering researchers at Konkuk University, urology faculty at Seoul National University College of Medicine, and researchers at Wonkwang University have reported a preclinical platform designed to use stem cells obtained from urine to help regenerate cavernous nerves damaged by prostate cancer surgery and support recovery of erectile function. The findings were published online in Bioactive Materials on September 11.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
Despite advances in prostate cancer surgery, approximately 60% to 70% of patients develop erectile dysfunction afterward. Injury to the cavernous nerves that regulate erectile function is a major cause; when these nerves are damaged, signaling to the corpus cavernosum can weaken or stop. Even during nerve recovery, cells in the corpus cavernosum can die and fibrosis can stiffen the tissue. Once structural changes occur, the condition can progress to refractory erectile dysfunction that does not respond to existing treatments.
Stem-cell-based regenerative approaches have generally been injected directly into tissue, which the researchers said makes it difficult to restore the damaged nerves themselves and allows cells to wash away. To address this, the team combined urine-derived stem cells with nerve growth factor (NGF) and a 3D-printed biodegradable scaffold.
Preclinical findings
The researchers first reprogrammed urine-derived stem cells into induced pluripotent stem cells, introduced the NGF gene, and differentiated the cells into neural crest cells. These cells secreted more than 1,000 times as much NGF as cells without the gene and retained differentiation capacity. The neural crest cells were then loaded onto the scaffold and applied to rats with injured cavernous nerves.
In the group receiving both cells and scaffold, erectile function indicators recovered to levels similar to those of normal rats. Animals receiving only one component showed partial improvement. The combination group also had reduced cell death and fibrosis in the tissue.
The researchers plan to further evaluate the platform in non-nerve-sparing surgery models and assess long-term durability to strengthen the case for clinical application.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
XellSmart’s iPSC-Derived Dopaminergic Neural Progenitor Cell Therapy Shows Motor Improvements in Phase I Parkinson’s Trial and Completes Phase II Enrollment
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
Ultragenyx Announces Approval of Fayuvi Gene Therapy for Sanfilippo Syndrome Type A
JAX-NYSCF Stem Cell Toolkit for Parkinson’s Disease
Cyllene Therapeutics’ Gene Therapy Receives FDA RMAT Designation for Neurogenic Detrusor Overactivity
Aspen Neuroscience Nabs FDA RMAT Designation for its Parkinson’s Cell Therapy
bit.bio Partners with myriamed to Add Cryopreserved Stem Cell-Derived Cardiomyocytes to Drug Discovery Portfolio







